Depakine

Phase 2Small molecule

CCentre d'Etude des Cellules Souches

Depakine is one of 7 small molecule programs targeting Wolfram syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Wolfram SyndromeActive, not recruiting

Wolfram SyndromePhase 2

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Wolfram Syndrome

#DrugCompanyPhaseTrials

Januvia

ZZydus Therapeutics Inc.

Phase 3

1 2

Ferriprox

Chiesi Farmaceutici S.p.A.

Phase 3

1 3

Acetadote

AArbor Pharmaceuticals, Inc.

Phase 3

1 4

Mounjaro

Eli Lilly

Phase 2

1 5

AMX0035

AAmylyx Pharmaceuticals Inc.

Phase 2

1 6

Byetta

AstraZeneca

Preclinical

1 7

Depakine

CCentre d'Etude des Cellules Souches

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Wolfram syndrome1 trial

Efficacy Study of Daily Administration of VPA in Patients Affected by Wolfram Syndrome

Unknown status·CCentre d'Etude des Cellules Souches·Phase 2·NCT04940572·23 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Depakine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Depakine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Depakine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Centre d'Etude des Cellules Souches company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCentre d'Etude des Cellules Souches

Depakine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Wolfram syndrome1 trial

References

Drug Info

Quick Facts

Related News